Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease
BackgroundST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL-33 binding, inhibiting receptor signaling. Altho...
Saved in:
Published in | Inflammatory bowel diseases Vol. 16; no. 7; pp. 1097 - 1107 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Oxford University Press
01.07.2010
Wiley Subscription Services, Inc., A Wiley Company |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BackgroundST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL-33 binding, inhibiting receptor signaling. Although ST2s has been associated with inflammatory processes in patients with sepsis, trauma, asthma, and autoimmunity, until now there are no reported studies showing the role of ST2/IL-33 in inflammatory bowel disease (IBD).MethodsExpression of ST2 and IL-33 was determined in serum and colonic biopsies from IBD patients. ST2 transcript and protein was determined by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA)/immunoblot, respectively, and IL-33 protein by ELISA. Intestinal mucosa localization of ST2 and IL-33 was conducted by immunofluorescence.ResultsST2s transcript in the colonic mucosa was mainly expressed in UC patients rather than Crohn's disease or control; however, ST2L mRNA remained constant in all samples. Total ST2 protein was significantly higher in mucosa samples from patients with active UC, with a predominant induction of ST2s that strongly correlates with serum ST2 levels. Mucosa IL-33 levels were higher in UC patients and serum levels were barely detected in all patient groups. ST2 and IL-33 are both abundantly expressed in the cytoplasm of epithelial cells of control subjects; however, in ulcerative colitis patients ST2 decreases and IL-33 showed cytoplasm-nuclear redistribution.ConclusionsThe novel association between the ST2/IL-33 system and IBD seems to identify that variations in this axis might regulate the inflammatory process in these diseases. Inflamm Bowel Dis 2010 |
---|---|
AbstractList | Background: ST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL-33 binding, inhibiting receptor signaling. Although ST2s has been associated with inflammatory processes in patients with sepsis, trauma, asthma, and autoimmunity, until now there are no reported studies showing the role of ST2/IL-33 in inflammatory bowel disease (IBD). Methods: Expression of ST2 and IL-33 was determined in serum and colonic biopsies from IBD patients. ST2 transcript and protein was determined by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA)/immunoblot, respectively, and IL-33 protein by ELISA. Intestinal mucosa localization of ST2 and IL-33 was conducted by immunofluorescence. Results: ST2s transcript in the colonic mucosa was mainly expressed in UC patients rather than Crohn's disease or control; however, ST2L mRNA remained constant in all samples. Total ST2 protein was significantly higher in mucosa samples from patients with active UC, with a predominant induction of ST2s that strongly correlates with serum ST2 levels. Mucosa IL-33 levels were higher in UC patients and serum levels were barely detected in all patient groups. ST2 and IL-33 are both abundantly expressed in the cytoplasm of epithelial cells of control subjects; however, in ulcerative colitis patients ST2 decreases and IL-33 showed cytoplasm-nuclear redistribution. Conclusions: The novel association between the ST2/IL-33 system and IBD seems to identify that variations in this axis might regulate the inflammatory process in these diseases. Inflamm Bowel Dis 2010. ST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL-33 binding, inhibiting receptor signaling. Although ST2s has been associated with inflammatory processes in patients with sepsis, trauma, asthma, and autoimmunity, until now there are no reported studies showing the role of ST2/IL-33 in inflammatory bowel disease (IBD). Expression of ST2 and IL-33 was determined in serum and colonic biopsies from IBD patients. ST2 transcript and protein was determined by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA)/immunoblot, respectively, and IL-33 protein by ELISA. Intestinal mucosa localization of ST2 and IL-33 was conducted by immunofluorescence. ST2s transcript in the colonic mucosa was mainly expressed in UC patients rather than Crohn's disease or control; however, ST2L mRNA remained constant in all samples. Total ST2 protein was significantly higher in mucosa samples from patients with active UC, with a predominant induction of ST2s that strongly correlates with serum ST2 levels. Mucosa IL-33 levels were higher in UC patients and serum levels were barely detected in all patient groups. ST2 and IL-33 are both abundantly expressed in the cytoplasm of epithelial cells of control subjects; however, in ulcerative colitis patients ST2 decreases and IL-33 showed cytoplasm-nuclear redistribution. The novel association between the ST2/IL-33 system and IBD seems to identify that variations in this axis might regulate the inflammatory process in these diseases. ST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL-33 binding, inhibiting receptor signaling. Although ST2s has been associated with inflammatory processes in patients with sepsis, trauma, asthma, and autoimmunity, until now there are no reported studies showing the role of ST2/IL-33 in inflammatory bowel disease (IBD).BACKGROUNDST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL-33 binding, inhibiting receptor signaling. Although ST2s has been associated with inflammatory processes in patients with sepsis, trauma, asthma, and autoimmunity, until now there are no reported studies showing the role of ST2/IL-33 in inflammatory bowel disease (IBD).Expression of ST2 and IL-33 was determined in serum and colonic biopsies from IBD patients. ST2 transcript and protein was determined by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA)/immunoblot, respectively, and IL-33 protein by ELISA. Intestinal mucosa localization of ST2 and IL-33 was conducted by immunofluorescence.METHODSExpression of ST2 and IL-33 was determined in serum and colonic biopsies from IBD patients. ST2 transcript and protein was determined by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA)/immunoblot, respectively, and IL-33 protein by ELISA. Intestinal mucosa localization of ST2 and IL-33 was conducted by immunofluorescence.ST2s transcript in the colonic mucosa was mainly expressed in UC patients rather than Crohn's disease or control; however, ST2L mRNA remained constant in all samples. Total ST2 protein was significantly higher in mucosa samples from patients with active UC, with a predominant induction of ST2s that strongly correlates with serum ST2 levels. Mucosa IL-33 levels were higher in UC patients and serum levels were barely detected in all patient groups. ST2 and IL-33 are both abundantly expressed in the cytoplasm of epithelial cells of control subjects; however, in ulcerative colitis patients ST2 decreases and IL-33 showed cytoplasm-nuclear redistribution.RESULTSST2s transcript in the colonic mucosa was mainly expressed in UC patients rather than Crohn's disease or control; however, ST2L mRNA remained constant in all samples. Total ST2 protein was significantly higher in mucosa samples from patients with active UC, with a predominant induction of ST2s that strongly correlates with serum ST2 levels. Mucosa IL-33 levels were higher in UC patients and serum levels were barely detected in all patient groups. ST2 and IL-33 are both abundantly expressed in the cytoplasm of epithelial cells of control subjects; however, in ulcerative colitis patients ST2 decreases and IL-33 showed cytoplasm-nuclear redistribution.The novel association between the ST2/IL-33 system and IBD seems to identify that variations in this axis might regulate the inflammatory process in these diseases.CONCLUSIONSThe novel association between the ST2/IL-33 system and IBD seems to identify that variations in this axis might regulate the inflammatory process in these diseases. Background: ST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL‐33 membrane receptor and belongs to the IL‐1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL‐33 binding, inhibiting receptor signaling. Although ST2s has been associated with inflammatory processes in patients with sepsis, trauma, asthma, and autoimmunity, until now there are no reported studies showing the role of ST2/IL‐33 in inflammatory bowel disease (IBD). Methods: Expression of ST2 and IL‐33 was determined in serum and colonic biopsies from IBD patients. ST2 transcript and protein was determined by reverse‐transcription polymerase chain reaction (RT‐PCR) and enzyme‐linked immunosorbent assay (ELISA)/immunoblot, respectively, and IL‐33 protein by ELISA. Intestinal mucosa localization of ST2 and IL‐33 was conducted by immunofluorescence. Results: ST2s transcript in the colonic mucosa was mainly expressed in UC patients rather than Crohn's disease or control; however, ST2L mRNA remained constant in all samples. Total ST2 protein was significantly higher in mucosa samples from patients with active UC, with a predominant induction of ST2s that strongly correlates with serum ST2 levels. Mucosa IL‐33 levels were higher in UC patients and serum levels were barely detected in all patient groups. ST2 and IL‐33 are both abundantly expressed in the cytoplasm of epithelial cells of control subjects; however, in ulcerative colitis patients ST2 decreases and IL‐33 showed cytoplasm‐nuclear redistribution. Conclusions: The novel association between the ST2/IL‐33 system and IBD seems to identify that variations in this axis might regulate the inflammatory process in these diseases. Inflamm Bowel Dis 2010 BackgroundST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL-33 binding, inhibiting receptor signaling. Although ST2s has been associated with inflammatory processes in patients with sepsis, trauma, asthma, and autoimmunity, until now there are no reported studies showing the role of ST2/IL-33 in inflammatory bowel disease (IBD).MethodsExpression of ST2 and IL-33 was determined in serum and colonic biopsies from IBD patients. ST2 transcript and protein was determined by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA)/immunoblot, respectively, and IL-33 protein by ELISA. Intestinal mucosa localization of ST2 and IL-33 was conducted by immunofluorescence.ResultsST2s transcript in the colonic mucosa was mainly expressed in UC patients rather than Crohn's disease or control; however, ST2L mRNA remained constant in all samples. Total ST2 protein was significantly higher in mucosa samples from patients with active UC, with a predominant induction of ST2s that strongly correlates with serum ST2 levels. Mucosa IL-33 levels were higher in UC patients and serum levels were barely detected in all patient groups. ST2 and IL-33 are both abundantly expressed in the cytoplasm of epithelial cells of control subjects; however, in ulcerative colitis patients ST2 decreases and IL-33 showed cytoplasm-nuclear redistribution.ConclusionsThe novel association between the ST2/IL-33 system and IBD seems to identify that variations in this axis might regulate the inflammatory process in these diseases. Inflamm Bowel Dis 2010 |
Author | Beltrán, Caroll J. Farfan, Nancy Heine, Claudio Hermoso, Marcela A. González, María Julieta Quera, Rodrigo López, Francisco Núñez, Lucía E. Díaz-Jiménez, David Candia, Enzo |
Author_xml | – sequence: 1 givenname: Caroll J. surname: Beltrán fullname: Beltrán, Caroll J. organization: 1Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile – sequence: 2 givenname: Lucía E. surname: Núñez fullname: Núñez, Lucía E. organization: 1Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile – sequence: 3 givenname: David surname: Díaz-Jiménez fullname: Díaz-Jiménez, David organization: 1Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile – sequence: 4 givenname: Nancy surname: Farfan fullname: Farfan, Nancy organization: 1Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile – sequence: 5 givenname: Enzo surname: Candia fullname: Candia, Enzo organization: 1Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile – sequence: 6 givenname: Claudio surname: Heine fullname: Heine, Claudio organization: 3Laboratory of Oncology and Molecular Genetics, Colorectal Surgery Unit, Las Condes Clinic, Santiago, Chile – sequence: 7 givenname: Francisco surname: López fullname: López, Francisco organization: 3Laboratory of Oncology and Molecular Genetics, Colorectal Surgery Unit, Las Condes Clinic, Santiago, Chile – sequence: 8 givenname: María Julieta surname: González fullname: González, María Julieta organization: 4Cell and Molecular Biology Program, Biomedical Sciences Institute, Faculty of Medicine, Universidad de Chile, Santiago, Chile – sequence: 9 givenname: Rodrigo surname: Quera fullname: Quera, Rodrigo organization: 5Gastroenterology Unit, Santiago, Chile – sequence: 10 givenname: Marcela A. surname: Hermoso fullname: Hermoso, Marcela A. organization: 1Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20014018$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkT1PwzAQhi1URGlh4A8gD0iIIa0dJ04yQvmqVImBsrBETnJRjZK42A5V-PWYfjAgUc7Dna3nvbPuHaBeoxpA6IySESXEH8usGPmURuEBOqYh414QB0HP1SSKPZIkcR8NjHlzqDvJEer7hNCA0PgYvU4WQovcgpafwkrVYFViuwDcqA-o8PPcH09nHmPYdMZCjWWDl46Dxhq8knbhHspK1LWwSnc4UysnKqQBYeAEHZaiMnC6zUP0cn83nzx6s6eH6eR65uWBT0IvyxOIMr_gNCoZ5X6Z5QxCkpehH0MiOMkKEgZcMAGFuwYJKXgchFyQKOQsLtkQXW76LrV6b8HYtJYmh6oSDajWpJGD3aQk_p9kLihjiSPPt2Sb1VCkSy1robt0tzgHXG2AXCtjNJQ_CCXptympMyVdm-LY8S82l3a9bKuFrPYpVrKC7u_W6fTmdqe42ChUu9zzlS-gCacn |
CitedBy_id | crossref_primary_10_1080_14712598_2020_1733964 crossref_primary_10_1155_2018_1827901 crossref_primary_10_1182_blood_2014_10_606830 crossref_primary_10_1016_j_ajg_2024_01_002 crossref_primary_10_1093_ajcp_aqv082 crossref_primary_10_1038_srep35403 crossref_primary_10_1111_ctr_13349 crossref_primary_10_1111_cts_13442 crossref_primary_10_3109_00365521_2016_1101245 crossref_primary_10_1155_2013_142492 crossref_primary_10_1007_s10753_011_9379_4 crossref_primary_10_3389_fimmu_2018_02432 crossref_primary_10_1186_2045_3701_4_72 crossref_primary_10_1189_jlb_3RU1114_563R crossref_primary_10_1097_MEG_0000000000001490 crossref_primary_10_1136_gutjnl_2011_301785 crossref_primary_10_1007_s00262_014_1624_x crossref_primary_10_1038_s41573_025_01158_9 crossref_primary_10_1155_2017_6592139 crossref_primary_10_1111_j_1365_2222_2011_03867_x crossref_primary_10_1016_j_prerep_2024_100002 crossref_primary_10_1159_000437327 crossref_primary_10_1124_jpet_114_222505 crossref_primary_10_2492_inflammregen_35_069 crossref_primary_10_1016_j_jss_2019_05_057 crossref_primary_10_1038_s41598_017_10465_0 crossref_primary_10_1038_s41598_021_89119_1 crossref_primary_10_3389_fimmu_2017_00979 crossref_primary_10_4103_ejdv_ejdv_37_21 crossref_primary_10_1073_pnas_1803613115 crossref_primary_10_1152_ajpregu_00300_2022 crossref_primary_10_1155_2018_3048941 crossref_primary_10_1111_cei_12896 crossref_primary_10_1038_mi_2016_14 crossref_primary_10_3389_fimmu_2025_1533335 crossref_primary_10_3389_fimmu_2019_01394 crossref_primary_10_3390_ijms24010623 crossref_primary_10_1111_imr_12974 crossref_primary_10_1128_IAI_02908_14 crossref_primary_10_3389_fimmu_2020_581445 crossref_primary_10_1111_jcmm_16297 crossref_primary_10_1073_pnas_1422445112 crossref_primary_10_2353_ajpath_2010_100378 crossref_primary_10_1016_j_jtauto_2019_100011 crossref_primary_10_1016_j_amjcard_2015_01_035 crossref_primary_10_1093_discim_kyac006 crossref_primary_10_1136_postgradmedj_2012_303461rep crossref_primary_10_1152_ajpgi_00280_2022 crossref_primary_10_1016_j_scitotenv_2018_06_329 crossref_primary_10_1586_erm_12_128 crossref_primary_10_3389_fimmu_2016_00695 crossref_primary_10_1155_2019_7947596 crossref_primary_10_1111_ajt_13542 crossref_primary_10_1002_eji_201041135 crossref_primary_10_1128_IAI_01307_12 crossref_primary_10_1016_j_semcancer_2019_05_001 crossref_primary_10_1016_j_lfs_2017_08_010 crossref_primary_10_1128_mBio_00383_13 crossref_primary_10_1172_JCI88625 crossref_primary_10_2119_molmed_2011_00428 crossref_primary_10_1177_1756283X11410770 crossref_primary_10_1007_s00535_022_01936_x crossref_primary_10_1155_2014_587376 crossref_primary_10_1016_j_cyto_2013_02_026 crossref_primary_10_1016_j_cca_2014_09_021 crossref_primary_10_1093_ibd_izae129 crossref_primary_10_1016_j_autrev_2019_03_012 crossref_primary_10_1016_j_intimp_2023_110653 crossref_primary_10_1016_j_jcmgh_2015_01_006 crossref_primary_10_1074_jbc_M116_769422 crossref_primary_10_1002_ibd_21638 crossref_primary_10_1021_acsptsci_3c00122 crossref_primary_10_1080_14767058_2018_1548601 crossref_primary_10_1016_j_cbi_2020_109315 crossref_primary_10_1016_j_phrs_2013_06_007 crossref_primary_10_1189_jlb_0810470 crossref_primary_10_3892_ol_2016_4626 crossref_primary_10_1038_s41598_017_00840_2 crossref_primary_10_1136_gutjnl_2019_319850 crossref_primary_10_3389_fimmu_2019_00364 crossref_primary_10_1186_s12876_016_0520_6 crossref_primary_10_3389_fimmu_2021_669787 crossref_primary_10_1016_j_lfs_2023_121868 crossref_primary_10_1371_journal_pone_0062144 crossref_primary_10_3390_ijms18102020 crossref_primary_10_1016_j_cyto_2018_08_009 crossref_primary_10_3389_fimmu_2019_00647 crossref_primary_10_1038_mi_2013_124 crossref_primary_10_4049_jimmunol_1201373 crossref_primary_10_1111_bph_13535 crossref_primary_10_1097_MIB_0000000000000512 crossref_primary_10_1177_2050640618792819 crossref_primary_10_1155_2014_423957 crossref_primary_10_18632_oncotarget_25768 crossref_primary_10_1152_ajplung_00305_2014 crossref_primary_10_3390_ijms22115792 crossref_primary_10_2310_JIM_0b013e31826d8fcb crossref_primary_10_1016_j_biopha_2021_111902 crossref_primary_10_15252_embj_2023113796 crossref_primary_10_3389_fimmu_2018_01700 crossref_primary_10_5217_ir_2018_16_1_26 crossref_primary_10_1038_s41385_019_0138_4 crossref_primary_10_1007_s11882_016_0652_3 crossref_primary_10_1097_MIB_0b013e3182a8759a crossref_primary_10_1371_journal_pone_0277576 crossref_primary_10_1136_gutjnl_2012_303920 crossref_primary_10_1007_s12028_021_01284_3 crossref_primary_10_1016_j_cyto_2012_02_008 crossref_primary_10_1016_j_gene_2022_146478 crossref_primary_10_1093_ibd_izab034 crossref_primary_10_1155_2013_608187 crossref_primary_10_1136_jim_2016_000062 crossref_primary_10_1155_2017_4810258 crossref_primary_10_3748_wjg_v20_i30_10262 crossref_primary_10_1007_s11030_021_10359_4 crossref_primary_10_1038_s41467_023_37849_3 crossref_primary_10_3389_fimmu_2018_02506 crossref_primary_10_1016_j_ijpharm_2023_123206 crossref_primary_10_1038_s41467_025_57879_3 crossref_primary_10_3390_ijms232113242 crossref_primary_10_1016_j_crohns_2013_12_021 crossref_primary_10_3389_fimmu_2019_02449 crossref_primary_10_1007_s11725_015_0608_4 crossref_primary_10_3389_fimmu_2023_1158323 crossref_primary_10_1073_pnas_1307321110 crossref_primary_10_1038_s41598_017_05716_z crossref_primary_10_1586_1744666X_2013_814428 crossref_primary_10_1016_j_celrep_2016_04_049 crossref_primary_10_1111_bph_13712 crossref_primary_10_1016_j_bcp_2023_115787 crossref_primary_10_1016_j_cyto_2017_06_017 crossref_primary_10_1371_journal_pone_0052252 crossref_primary_10_1021_acs_molpharmaceut_1c00002 crossref_primary_10_1097_MIB_0000000000000532 crossref_primary_10_1111_imm_12111 crossref_primary_10_1002_slct_202403179 crossref_primary_10_3390_diagnostics12102344 crossref_primary_10_1016_j_cytogfr_2015_07_017 crossref_primary_10_1038_s41598_021_82096_5 crossref_primary_10_1136_gutjnl_2023_329963 crossref_primary_10_1177_1756284819869141 crossref_primary_10_1016_j_cytogfr_2019_04_004 crossref_primary_10_1111_ctr_14616 crossref_primary_10_3390_ijms26010121 crossref_primary_10_1177_1721727X1401200209 crossref_primary_10_1093_ibd_izae292 crossref_primary_10_1159_000445133 crossref_primary_10_1111_coa_13647 crossref_primary_10_1007_s00535_010_0245_1 crossref_primary_10_1016_j_ajpath_2015_11_028 crossref_primary_10_1016_j_ejphar_2022_175379 crossref_primary_10_1016_j_jaci_2016_09_049 crossref_primary_10_3390_biomedicines12112562 crossref_primary_10_1097_01_MIB_0000437616_37000_41 crossref_primary_10_1007_s00535_014_0982_7 crossref_primary_10_1007_s12079_022_00695_x crossref_primary_10_1038_s41374_019_0329_3 crossref_primary_10_1152_physrev_00005_2021 crossref_primary_10_1016_j_intimp_2022_108887 crossref_primary_10_1177_09636897231177377 crossref_primary_10_3389_fmed_2017_00126 crossref_primary_10_1038_nature13577 crossref_primary_10_1155_2015_864597 crossref_primary_10_1016_j_cca_2019_07_033 crossref_primary_10_1016_j_imlet_2015_10_004 crossref_primary_10_1038_s41598_020_60155_7 crossref_primary_10_1186_s13317_019_0110_z crossref_primary_10_1016_j_bcp_2018_01_010 crossref_primary_10_1016_j_imbio_2011_10_023 crossref_primary_10_1016_j_imbio_2015_06_003 crossref_primary_10_1080_2162402X_2015_1062966 crossref_primary_10_1371_journal_pone_0056866 crossref_primary_10_1016_j_intimp_2017_02_006 crossref_primary_10_1111_imm_12174 crossref_primary_10_1128_IAI_00707_20 crossref_primary_10_3389_fimmu_2019_01091 crossref_primary_10_2310_JIM_0b013e31828deed2 crossref_primary_10_1038_mi_2011_22 crossref_primary_10_1002_pmic_201400303 crossref_primary_10_1186_1755_1536_5_18 crossref_primary_10_1007_s10753_018_0776_9 crossref_primary_10_1016_j_imlet_2016_08_007 crossref_primary_10_1111_1348_0421_12381 crossref_primary_10_1155_2022_1358858 crossref_primary_10_1038_s41598_025_91202_w crossref_primary_10_1016_j_cyto_2012_06_014 crossref_primary_10_1212_WNL_0000000000206764 crossref_primary_10_1016_j_intimp_2015_01_012 crossref_primary_10_3389_fimmu_2017_00475 |
Cites_doi | 10.1016/j.immuni.2009.05.007 10.2353/ajpath.2008.080014 10.1016/j.bbrc.2006.10.166 10.1055/s-2008-1039044 10.1016/j.cyto.2007.09.013 10.1074/jbc.M704916200 10.1007/s00134-004-2184-x 10.1016/0167-5699(94)90217-8 10.4049/jimmunol.180.4.2443 10.1073/pnas.0606854104 10.1073/pnas.0812690106 10.1002/eji.200636520 10.1038/mp.2009.10 10.1038/labinvest.3700663 10.1016/S0140-6736(07)60750-8 10.1164/ajrccm.164.2.2008120 10.1006/bbrc.1997.6810 10.1172/JCI19836 10.1378/chest.124.4.1206 10.1164/rccm.200805-666OC 10.1073/pnas.0705939104 10.1016/j.immuni.2005.09.015 10.1016/j.bbrc.2009.07.018 10.1002/art.24305 10.1016/j.jacc.2008.07.042 10.4067/S0034-98872008000300014 10.1016/j.cyto.2007.11.001 10.1016/0014-5793(89)81679-5 10.1006/bbrc.2001.5090 10.4049/jimmunol.178.9.5859 10.1074/jbc.M901744200 10.4049/jimmunol.173.1.145 10.1006/bbrc.1999.1469 10.1155/2005/269076 10.1684/ecn.2009.0142 10.1084/jem.20071868 |
ContentType | Journal Article |
Copyright | Copyright © 2009 Crohn's & Colitis Foundation of America, Inc. 2009 Copyright © 2009 Crohn's & Colitis Foundation of America, Inc. |
Copyright_xml | – notice: Copyright © 2009 Crohn's & Colitis Foundation of America, Inc. 2009 – notice: Copyright © 2009 Crohn's & Colitis Foundation of America, Inc. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7QL 7T5 C1K H94 |
DOI | 10.1002/ibd.21175 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Bacteriology Abstracts (Microbiology B) Immunology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1536-4844 |
EndPage | 1107 |
ExternalDocumentID | 20014018 10_1002_ibd_21175 IBD21175 10.1002/ibd.21175 |
Genre | article Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GrantInformation_xml | – fundername: FONDECYT funderid: 1070954; OAIC 167/06 |
GroupedDBID | --- .Z2 0R~ 1OC 3WU 4.4 48X 53G 5GY 5VS 5WD 66C 7O~ 8-0 8-1 8UM AAAXR AABZA AACZT AAKAS AAPQZ AAPXW AARHZ AARTV AAUAY AAVAP AAYEP ABBUW ABDFA ABEJV ABGNP ABJNI ABNHQ ABOCM ABPQP ABPTD ABQNK ABVGC ABWST ABXVJ ABXVV ABZAD ACDDN ACEWG ACGFO ACGFS ACUTJ ACWDW ACWRI ACXNZ ACXQS ACYHN ADBBV ADBIZ ADGZP ADIPN ADQBN ADRTK ADVEK ADZCM AENEX AETBJ AFBPY AFFZL AFOFC AFTRI AFXAL AFZJQ AGINJ AGQXC AGUTN AHMBA AHMMS AIJEX AIZYK AJAOE AJEEA AJNYG ALMA_UNASSIGNED_HOLDINGS ATGXG AWKKM BAYMD BCRHZ BEYMZ BOYCO BTRTY C45 CDBKE CS3 DAKXR DR2 DU5 E.X E3Z EBS EJD ENERS EX3 F5P FECEO FL- FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H0~ HZ~ IN~ IX1 KBUDW KOP KSI KSN LAW LH4 LW6 MHKGH NNB NOMLY NOYVH NU- NVLIB N~7 N~B O9- OAUYM OCZFY ODMLO OIG OJZSN OPAEJ OVD OWPYF P2P PAFKI PQQKQ QRW ROL ROX RUSNO RX1 S4S TEORI V2E W99 WOW XV2 YAYTL YKOAZ YXANX ZFV 31~ 8F7 AAJQQ AAPGJ AAUQX AAWDT ACFRR ACZBC AFUWQ AFYAG AGKRT AGMDO AHRYX APJGH AQDSO AQKUS AVNTJ EIHJH H13 IAO IHR ITC MBLQV OCUKA ORVUJ TMA WOQ Y6R 7X7 88E 8FI 8FJ AAYXX ABUWG ADNBA AEMQT AFKRA AGORE AJNCP ALXQX BENPR CCPQU CITATION FYUFA HMCUK JXSIZ M1P PHGZM PHGZT PJZUB PPXIY PSQYO UKHRP AFFQV CGR CUY CVF ECM EIF NPM 7X8 7QL 7T5 C1K H94 |
ID | FETCH-LOGICAL-c4205-bc9e7b2d617f3162fbc3e50cf528e9a60bd0546a3aed9a6490d68456a075638f3 |
IEDL.DBID | DR2 |
ISSN | 1078-0998 1536-4844 |
IngestDate | Fri Jul 11 04:38:53 EDT 2025 Mon Jul 21 11:42:26 EDT 2025 Wed Feb 19 02:41:14 EST 2025 Sun Aug 03 02:35:16 EDT 2025 Thu Apr 24 22:54:44 EDT 2025 Wed Jan 22 17:05:15 EST 2025 Sat Feb 08 08:13:08 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | ST2 Crohn's disease ulcerative colitis IL-33 inflammatory bowel disease |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4205-bc9e7b2d617f3162fbc3e50cf528e9a60bd0546a3aed9a6490d68456a075638f3 |
Notes | The last 2 authors share senior authorship. The first 3 authors contributed equally to the article. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | http://americanae.aecid.es/americanae/es/registros/registro.do?tipoRegistro=MTD&idBib=3272597 |
PMID | 20014018 |
PQID | 733331339 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_745642098 proquest_miscellaneous_733331339 pubmed_primary_20014018 crossref_primary_10_1002_ibd_21175 crossref_citationtrail_10_1002_ibd_21175 wiley_primary_10_1002_ibd_21175_IBD21175 oup_primary_10_1002_ibd_21175 |
PublicationCentury | 2000 |
PublicationDate | July 2010 |
PublicationDateYYYYMMDD | 2010-07-01 |
PublicationDate_xml | – month: 07 year: 2010 text: July 2010 |
PublicationDecade | 2010 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: Hoboken – name: England |
PublicationTitle | Inflammatory bowel diseases |
PublicationTitleAlternate | Inflamm Bowel Dis |
PublicationYear | 2010 |
Publisher | Oxford University Press Wiley Subscription Services, Inc., A Wiley Company |
Publisher_xml | – name: Oxford University Press – name: Wiley Subscription Services, Inc., A Wiley Company |
References | 2007; 104 1997; 235 2007; 369 2001; 164 2009; 20 2001; 284 2007; 282 2005; 133 1989; 258 2009; 60 1999; 264 2009; 179 2008; 205 2006; 351 2008; 52 2005; 23 2007; 37 2008; 180 2004; 30 2009; 14 2007; 178 2009; 57 2005; 19 2004; 113 2009; 31 2004; 173 2006; 69 2009; 387 1994; 15 2008; 136 2008; 41 2007; 40 2009; 284 2007; 87 2003; 124 2008; 173 2009; 106 Schmitz (2025060906215214600_R11-7) 2005; 23 Kumar (2025060906215214600_R24-7) 1997; 235 Fuss (2025060906215214600_R28-7) 2004; 113 Chapuis (2025060906215214600_R16-7) 2009; 14 Moulin (2025060906215214600_R25-7) 2007; 40 Kuchler (2025060906215214600_R27-7) 2008; 173 Carriere (2025060906215214600_R12-7) 2007; 104 Leung (2025060906215214600_R18-7) 2004; 173 Baumgart (2025060906215214600_R1-7) 2007; 369 Cayrol (2025060906215214600_R33-7) 2009; 106 Rehman (2025060906215214600_R7-7) 2008; 52 Kuroiwa (2025060906215214600_R23-7) 2001; 284 Tominaga (2025060906215214600_R10-7) 1999; 264 Iikura (2025060906215214600_R30-7) 2007; 87 Palmer (2025060906215214600_R13-7) 2009; 60 Verstege (2025060906215214600_R37-7) 2006; 69 Yin (2025060906215214600_R21-7) 2006; 351 Fichtner-Feigl (2025060906215214600_R31-7) 2007; 178 Szerafin (2025060906215214600_R19-7) 2009; 57 Mangan (2025060906215214600_R15-7) 2007; 37 Tominaga (2025060906215214600_R4-7) 1989; 258 Kearley (2025060906215214600_R14-7) 2009; 179 Miller (2025060906215214600_R17-7) 2008; 205 Colotta (2025060906215214600_R26-7) 1994; 15 Brunner (2025060906215214600_R9-7) 2004; 30 Hayakawa (2025060906215214600_R20-7) 2007; 282 Luthi (2025060906215214600_R36-7) 2009; 31 Sepulveda (2025060906215214600_R2-7) 2008; 136 Beltran (2025060906215214600_R3-7) 2009; 20 Becerra (2025060906215214600_R8-7) 2008; 41 Figueroa (2025060906215214600_R38-7) 2005; 133 Ali (2025060906215214600_R29-7) 2007; 104 Oshikawa (2025060906215214600_R5-7) 2001; 164 Silverberg (2025060906215214600_R22-7) 2005; 19 Talabot-Ayer (2025060906215214600_R35-7) 2009; 284 Hayakawa (2025060906215214600_R34-7) 2009; 387 Tajima (2025060906215214600_R6-7) 2003; 124 Humphreys (2025060906215214600_R32-7) 2008; 180 |
References_xml | – volume: 69 start-page: 406 year: 2006 end-page: 416 article-title: Apoptosis as a therapeutic paradigm in inflammatory bowel diseases publication-title: Acta Gastroenterol Belg. – volume: 178 start-page: 5859 year: 2007 end-page: 5870 article-title: Induction of IL‐13 triggers TGF‐beta1‐dependent tissue fibrosis in chronic 2,4,6‐trinitrobenzene sulfonic acid colitis publication-title: J Immunol. – volume: 23 start-page: 479 year: 2005 end-page: 490 article-title: IL‐33, an interleukin‐1‐like cytokine that signals via the IL‐1 receptor‐related protein ST2 and induces T helper type 2‐associated cytokines publication-title: Immunity. – volume: 41 start-page: 114 year: 2008 end-page: 120 article-title: Elevated levels of soluble ST2 protein in dengue virus infected patients publication-title: Cytokine. – volume: 133 start-page: 1295 year: 2005 end-page: 1304 article-title: Inflammatory bowel disease: experience of two Chilean centers publication-title: Rev Med Chile. – volume: 284 start-page: 19420 year: 2009 end-page: 19426 article-title: Interleukin‐33 is biologically active independently of caspase‐1 cleavage publication-title: J Biol Chem. – volume: 258 start-page: 301 year: 1989 end-page: 304 article-title: A putative protein of a growth specific cDNA from BALB/c‐3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor publication-title: FEBS Lett. – volume: 124 start-page: 1206 year: 2003 end-page: 1214 article-title: The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis publication-title: Chest. – volume: 173 start-page: 145 year: 2004 end-page: 150 article-title: A novel therapy of murine collagen‐induced arthritis with soluble T1/ST2 publication-title: J Immunol. – volume: 15 start-page: 562 year: 1994 end-page: 566 article-title: The type II ‘decoy’ receptor: a novel regulatory pathway for interleukin 1 publication-title: Immunol Today. – volume: 40 start-page: 216 year: 2007 end-page: 225 article-title: Interleukin (IL)‐33 induces the release of pro‐inflammatory mediators by mast cells publication-title: Cytokine. – volume: 235 start-page: 474 year: 1997 end-page: 478 article-title: Expression of ST2, an interleukin‐1 receptor homologue, is induced by proinflammatory stimuli publication-title: Biochem Biophys Res Commun. – volume: 173 start-page: 1229 year: 2008 end-page: 1242 article-title: Nuclear interleukin‐33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation publication-title: Am J Pathol. – volume: 264 start-page: 14 year: 1999 end-page: 18 article-title: Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT‐7/GM publication-title: Biochem Biophys Res Commun. – volume: 87 start-page: 971 year: 2007 end-page: 978 article-title: IL‐33 can promote survival, adhesion and cytokine production in human mast cells publication-title: Lab Invest. – volume: 19 start-page: 5 issue: suppl A year: 2005 end-page: 36 article-title: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology publication-title: Can J Gastroenterol. – volume: 37 start-page: 1302 year: 2007 end-page: 1312 article-title: T1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation publication-title: Eur J Immunol. – volume: 104 start-page: 18660 year: 2007 end-page: 18665 article-title: IL‐1 receptor accessory protein is essential for IL‐33‐induced activation of T lymphocytes and mast cells publication-title: Proc Natl Acad Sci USA. – volume: 387 start-page: 218 year: 2009 end-page: 222 article-title: Mature interleukin‐33 is produced by calpain‐mediated cleavage in vivo publication-title: Biochem Biophys Res Commun. – volume: 369 start-page: 1627 year: 2007 end-page: 1640 article-title: Inflammatory bowel disease: cause and immunobiology publication-title: Lancet. – volume: 57 start-page: 25 year: 2009 end-page: 29 article-title: Secretion of soluble ST2—possible explanation for systemic immunosuppression after heart surgery publication-title: Thorac Cardiovasc Surg. – volume: 351 start-page: 940 year: 2006 end-page: 946 article-title: Pretreatment with soluble ST2 reduces warm hepatic ischemia/reperfusion injury publication-title: Biochem Biophys Res Commun. – volume: 52 start-page: 1458 year: 2008 end-page: 1465 article-title: Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure publication-title: J Am Coll Cardiol. – volume: 60 start-page: 738 year: 2009 end-page: 749 article-title: Inhibition of interleukin‐33 signaling attenuates the severity of experimental arthritis publication-title: Arthritis Rheum. – volume: 180 start-page: 2443 year: 2008 end-page: 2449 article-title: IL‐33, a potent inducer of adaptive immunity to intestinal nematodes publication-title: J Immunol. – volume: 205 start-page: 339 year: 2008 end-page: 346 article-title: IL‐33 reduces the development of atherosclerosis publication-title: J Exp Med. – volume: 282 start-page: 26369 year: 2007 end-page: 26380 article-title: Soluble ST2 blocks interleukin‐33 signaling in allergic airway inflammation publication-title: J Biol Chem. – volume: 104 start-page: 282 year: 2007 end-page: 287 article-title: IL‐33, the IL‐1‐like cytokine ligand for ST2 receptor, is a chromatin‐associated nuclear factor in vivo publication-title: Proc Natl Acad Sci USA. – volume: 284 start-page: 1104 year: 2001 end-page: 1108 article-title: Identification of human ST2 protein in the sera of patients with autoimmune diseases publication-title: Biochem Biophys Res Commun. – volume: 136 start-page: 367 year: 2008 end-page: 375 article-title: [Inflammatory bowel diseases: an immunological approach.] publication-title: Rev Med Chil. – volume: 179 start-page: 772 year: 2009 end-page: 781 article-title: Resolution of allergic inflammation and AHR is dependent upon disruption of the T1/ST2‐IL‐33 pathway publication-title: Am J Respir Crit Care Med. – volume: 30 start-page: 1468 year: 2004 end-page: 1473 article-title: Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma publication-title: Intensive Care Med. – volume: 113 start-page: 1490 year: 2004 end-page: 1497 article-title: Nonclassical CD1d‐restricted NK T cells that produce IL‐13 characterize an atypical Th2 response in ulcerative colitis publication-title: J Clin Invest. – volume: 31 start-page: 84 year: 2009 end-page: 98 article-title: Suppression of interleukin‐33 bioactivity through proteolysis by apoptotic caspases publication-title: Immunity. – volume: 20 start-page: 33 year: 2009 end-page: 38 article-title: Peripheral cytokine profile in Chilean patients with Crohn's disease and ulcerative colitis publication-title: Eur Cytokine Netw. – volume: 106 start-page: 9021 year: 2009 end-page: 9026 article-title: The IL‐1‐like cytokine IL‐33 is inactivated after maturation by caspase‐1 publication-title: Proc Natl Acad Sci USA. – volume: 164 start-page: 277 year: 2001 end-page: 281 article-title: Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation publication-title: Am J Respir Crit Care Med. – volume: 14 start-page: 1004 year: 2009 end-page: 1016 article-title: Transcriptomic and genetic studies identify IL‐33 as a candidate gene for Alzheimer's disease publication-title: Mol Psychiatry. – volume: 31 start-page: 84 year: 2009 ident: 2025060906215214600_R36-7 publication-title: Immunity. doi: 10.1016/j.immuni.2009.05.007 – volume: 173 start-page: 1229 year: 2008 ident: 2025060906215214600_R27-7 publication-title: Am J Pathol. doi: 10.2353/ajpath.2008.080014 – volume: 351 start-page: 940 year: 2006 ident: 2025060906215214600_R21-7 publication-title: Biochem Biophys Res Commun. doi: 10.1016/j.bbrc.2006.10.166 – volume: 57 start-page: 25 year: 2009 ident: 2025060906215214600_R19-7 publication-title: Thorac Cardiovasc Surg. doi: 10.1055/s-2008-1039044 – volume: 40 start-page: 216 year: 2007 ident: 2025060906215214600_R25-7 publication-title: Cytokine. doi: 10.1016/j.cyto.2007.09.013 – volume: 282 start-page: 26369 year: 2007 ident: 2025060906215214600_R20-7 publication-title: J Biol Chem. doi: 10.1074/jbc.M704916200 – volume: 30 start-page: 1468 year: 2004 ident: 2025060906215214600_R9-7 publication-title: Intensive Care Med. doi: 10.1007/s00134-004-2184-x – volume: 15 start-page: 562 year: 1994 ident: 2025060906215214600_R26-7 publication-title: Immunol Today. doi: 10.1016/0167-5699(94)90217-8 – volume: 180 start-page: 2443 year: 2008 ident: 2025060906215214600_R32-7 publication-title: J Immunol. doi: 10.4049/jimmunol.180.4.2443 – volume: 104 start-page: 282 year: 2007 ident: 2025060906215214600_R12-7 publication-title: Proc Natl Acad Sci USA. doi: 10.1073/pnas.0606854104 – volume: 106 start-page: 9021 year: 2009 ident: 2025060906215214600_R33-7 publication-title: Proc Natl Acad Sci USA. doi: 10.1073/pnas.0812690106 – volume: 37 start-page: 1302 year: 2007 ident: 2025060906215214600_R15-7 publication-title: Eur J Immunol. doi: 10.1002/eji.200636520 – volume: 14 start-page: 1004 year: 2009 ident: 2025060906215214600_R16-7 publication-title: Mol Psychiatry. doi: 10.1038/mp.2009.10 – volume: 87 start-page: 971 year: 2007 ident: 2025060906215214600_R30-7 publication-title: Lab Invest. doi: 10.1038/labinvest.3700663 – volume: 369 start-page: 1627 year: 2007 ident: 2025060906215214600_R1-7 publication-title: Lancet. doi: 10.1016/S0140-6736(07)60750-8 – volume: 164 start-page: 277 year: 2001 ident: 2025060906215214600_R5-7 publication-title: Am J Respir Crit Care Med. doi: 10.1164/ajrccm.164.2.2008120 – volume: 235 start-page: 474 year: 1997 ident: 2025060906215214600_R24-7 publication-title: Biochem Biophys Res Commun. doi: 10.1006/bbrc.1997.6810 – volume: 113 start-page: 1490 year: 2004 ident: 2025060906215214600_R28-7 publication-title: J Clin Invest. doi: 10.1172/JCI19836 – volume: 124 start-page: 1206 year: 2003 ident: 2025060906215214600_R6-7 publication-title: Chest. doi: 10.1378/chest.124.4.1206 – volume: 179 start-page: 772 year: 2009 ident: 2025060906215214600_R14-7 publication-title: Am J Respir Crit Care Med. doi: 10.1164/rccm.200805-666OC – volume: 104 start-page: 18660 year: 2007 ident: 2025060906215214600_R29-7 publication-title: Proc Natl Acad Sci USA. doi: 10.1073/pnas.0705939104 – volume: 23 start-page: 479 year: 2005 ident: 2025060906215214600_R11-7 publication-title: Immunity. doi: 10.1016/j.immuni.2005.09.015 – volume: 69 start-page: 406 year: 2006 ident: 2025060906215214600_R37-7 publication-title: Acta Gastroenterol Belg. – volume: 387 start-page: 218 year: 2009 ident: 2025060906215214600_R34-7 publication-title: Biochem Biophys Res Commun. doi: 10.1016/j.bbrc.2009.07.018 – volume: 60 start-page: 738 year: 2009 ident: 2025060906215214600_R13-7 publication-title: Arthritis Rheum. doi: 10.1002/art.24305 – volume: 52 start-page: 1458 year: 2008 ident: 2025060906215214600_R7-7 publication-title: J Am Coll Cardiol. doi: 10.1016/j.jacc.2008.07.042 – volume: 136 start-page: 367 year: 2008 ident: 2025060906215214600_R2-7 publication-title: Rev Med Chil. doi: 10.4067/S0034-98872008000300014 – volume: 41 start-page: 114 year: 2008 ident: 2025060906215214600_R8-7 publication-title: Cytokine. doi: 10.1016/j.cyto.2007.11.001 – volume: 258 start-page: 301 year: 1989 ident: 2025060906215214600_R4-7 publication-title: FEBS Lett. doi: 10.1016/0014-5793(89)81679-5 – volume: 284 start-page: 1104 year: 2001 ident: 2025060906215214600_R23-7 publication-title: Biochem Biophys Res Commun. doi: 10.1006/bbrc.2001.5090 – volume: 178 start-page: 5859 year: 2007 ident: 2025060906215214600_R31-7 publication-title: J Immunol. doi: 10.4049/jimmunol.178.9.5859 – volume: 284 start-page: 19420 year: 2009 ident: 2025060906215214600_R35-7 publication-title: J Biol Chem. doi: 10.1074/jbc.M901744200 – volume: 173 start-page: 145 year: 2004 ident: 2025060906215214600_R18-7 publication-title: J Immunol. doi: 10.4049/jimmunol.173.1.145 – volume: 264 start-page: 14 year: 1999 ident: 2025060906215214600_R10-7 publication-title: Biochem Biophys Res Commun. doi: 10.1006/bbrc.1999.1469 – volume: 19 start-page: 5 year: 2005 ident: 2025060906215214600_R22-7 publication-title: Can J Gastroenterol. doi: 10.1155/2005/269076 – volume: 20 start-page: 33 year: 2009 ident: 2025060906215214600_R3-7 publication-title: Eur Cytokine Netw. doi: 10.1684/ecn.2009.0142 – volume: 205 start-page: 339 year: 2008 ident: 2025060906215214600_R17-7 publication-title: J Exp Med. doi: 10.1084/jem.20071868 – volume: 133 start-page: 1295 year: 2005 ident: 2025060906215214600_R38-7 publication-title: Rev Med Chile. |
SSID | ssj0020209 |
Score | 2.4167228 |
Snippet | BackgroundST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The... Background: ST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL‐33 membrane receptor and belongs to the IL‐1R family.... ST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble... Background: ST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family.... |
SourceID | proquest pubmed crossref wiley oup |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1097 |
SubjectTerms | Adolescent Adult Aged Blotting, Western Case-Control Studies Colitis, Ulcerative - genetics Colitis, Ulcerative - metabolism Crohn Disease - genetics Crohn Disease - metabolism Crohn's disease Female Humans IL‐33 inflammatory bowel disease Interleukin-1 Receptor-Like 1 Protein Interleukin-33 Interleukins - genetics Interleukins - metabolism Intestinal Mucosa - metabolism Intestinal Mucosa - pathology Male Middle Aged Receptors, Cell Surface - genetics Receptors, Cell Surface - metabolism Reverse Transcriptase Polymerase Chain Reaction RNA, Messenger - genetics ST2 ulcerative colitis Young Adult |
Title | Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fibd.21175 https://www.ncbi.nlm.nih.gov/pubmed/20014018 https://www.proquest.com/docview/733331339 https://www.proquest.com/docview/745642098 |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4BlRAXaHkuLSsLceCS3azz2EQ9dbcgQIAQD2kPSFHsjKUVkCB2FyRO_Qn9jf0lHdtJ2kUtQuSUxLbieGbsz57xZ4Ad0luBsfKdCBU6fqAiJxJCOb7ELAtckYXmHLKT0_Dgyj8aBIMZ-FrthbH8EPWCm7YM019rA0_FqP2HNHQoshbXRJPU_-pYLQ2IzmvqKJrTm_AOmt1o934cVaxCLm_XJafGoqn9bX_BzGnUaoad_SW4ripso01uWpOxaMnnF1yO7_yjj7BYwlH2zerPJ5jBfBnmT0qH-wpc92tCZ7tfkxWKEWZkefGIt-zikrcPj3_9-Ol5zHJCs2HOSq7WEdOLvPRCkdbdGW8-E8UTFSu9Qqtwtb932T9wygMZHOlzN3CEjLEreEaoR3mdkCshPQxcqQIeYZyGJFpCgGHqpZjRox-7WRgRQksJl5CdK28N5vIixw1gAdL4iChRE_gFMkw7krRDEYJQimY4vAG7lWgSWbKV60MzbhPLs8wTaq3EtFYDtuus95ai41-Ztki-r6WzSvIJGZj2mqQ5FpNR0vXoopl8_EoWzclD-hY1YN0qTf0hbgiMOpSya0T__xokh73v5mbz7Vk_w4KNZtDhw19gbvwwwS0CSWPRhNnuoNuED72907PzprGN3_wfDpM |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwED-NIo29wDbY6GDMmvawl7Sp86eJxAtsTO3W9mF00h5AUeycpYmSINqCtCc-Ap-RT8LZTrIVbdVEnpLYURzfXfw7n_07gAPSW4Gx8p0IFTp-oCInEkI5vsQsC1yRhSYP2XAU9i7808vgcgXeVnthLD9EPeGmLcP8r7WB6wnp9g1r6JXIWlwzTT6Cxzqjt3GozmvyKPLqzQIP8m90gD-OKl4hl7frRxdGo4UdbreA5iJuNQPPyTP4XDXZrjf50prPREte_8Pm-L_ftA5PS0TK3lkV2oAVzDdhdVjG3J_Dp6Oa09lu2WSFYgQbWV78wAn7OObt_uDPr9-exywtNLvKWUnXOmV6npduKFK8ryagz0Txkx4rA0Mv4OLkw_io55Q5GRzpczdwhIyxK3hGwEd5nZArIT0MXKkCHmGchiRdAoFh6qWY0aUfu1kYEUhLCZqQqStvCxp5keNLYAHSEIkoUXP4BTJMO5IURBGIUIqcHN6Ew0o2iSwJy3XejEliqZZ5Qr2VmN5qwn5d9Ztl6bir0i4JeFk5q0SfkI3pwEmaYzGfJl2PDnLm4yVVNC0PKVzUhG2rNfWLuOEw6lDJoZH9_S1I-u-PzcnOw6vuwZPeeDhIBv3R2StYs4sb9Gri19CYfZ_jLmGmmXhjTOMv96EQLQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwED9tQ6r2Mv6MsQIDa9pDX9Kmzp8m4glWqnZsE4JO6kOlKHbOUkWXTGsLEk98BD4jn4SznQQ6wTQtT0l8URzfXfw7n_0zwBHZrcBY-U6ECh0_UJETCaEcX2KWBa7IQrMP2dl5OLzwTybBZAPeVGthLD9EPeCmPcP8r7WDX2Wq84c0dCayNtdEk5vwwA_dSJt0_1PNHUVBvZnfQeGNzu_HUUUr5PJO_ehaZ7S2wO0vnLkOW02_M3gI06rGdrrJl_ZqKdry-w0yx3t-0iPYKfEoe2sN6DFsYP4EGmdlxn0Xpsc1o7NdsMkKxQg0srz4inP2ecw7o9NfP356HrOk0GyWs5KsdcH0KC_dUGR2lyadz0TxjR4r00JP4WLwfnw8dModGRzpczdwhIyxJ3hGsEd53ZArIT0MXKkCHmGchqRbgoBh6qWY0aUfu1kYEURLCZiQoytvD7byIsd9YAFSB4koUTP4BTJMu5LMQxGEUIpCHN6EVqWaRJZ05XrXjHliiZZ5Qq2VmNZqwmEtemU5Ov4ldED6va2cVZpPyMN02iTNsVgtkp5HB4Xy8S0impSH7C1qwjNrNPWLuGEw6lJJy6j-_zVIRu_65uT53UVfQ-Njf5Ccjs4_vIBtO7NBTyV-CVvL6xUeEGBailfGMX4D16cO5Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterization+of+the+novel+ST2%2FIL-33+system+in+patients+with+inflammatory+bowel+disease&rft.jtitle=Inflammatory+bowel+diseases&rft.au=Beltr%C3%A1n%2C+Caroll+J&rft.au=N%C3%BA%C3%B1ez%2C+Luc%C3%ADa+E&rft.au=D%C3%ADaz-Jim%C3%A9nez%2C+David&rft.au=Farfan%2C+Nancy&rft.date=2010-07-01&rft.eissn=1536-4844&rft.volume=16&rft.issue=7&rft.spage=1097&rft_id=info:doi/10.1002%2Fibd.21175&rft_id=info%3Apmid%2F20014018&rft.externalDocID=20014018 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0998&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0998&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0998&client=summon |